Nanosonics Limited (NAN.AX)
Nanosonics Limited operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Macquarie Park, NSW, AU. The stock last traded at $3.54, up 0.14% on the session, giving a market capitalisation of $1.06B. Its beta of 1.20 implies it has historically moved more than the broad market.
Nanosonics Limited, along with its subsidiaries, functions as a global infection prevention enterprise with operations in Australia and beyond. The company focuses on the production and distribution of its trophon ultrasound probe disinfection system, including all related supplies and accessories. Additionally, it dedicates resources to the exploration, development, and market launch of innovative infection control, decontamination products, and their associated technologies. Key offerings from Nanosonics include trophon2, an advanced device for high-level disinfection of ultrasound probes; trophon EPR, a low-temperature, high-level disinfection method specifically for intra-cavity ultrasound probes; and Nanosonics AuditPro, a comprehensive solution for managing compliance with infection control workflows. Established in 2000, Nanosonics Limited is headquartered in Macquarie Park, Australia.
Nanosonics Limited is most often compared with the following Healthcare names: